Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function

Endocrinology

Volumn 143, Issue 12, 2002, Pages 4599-4608

  Adam, Rosalyn M ^a   Kim, Jayoung ^a   Lin, Jianqing ^a   Orsola, Anna ^a   Zhuang, Liyan ^a   Rice, Dana C ^a   Freeman, Michael R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; DIMETHYL SULFOXIDE; ENOLASE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGENIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CASTRATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DIFFUSION; EVIDENCE BASED MEDICINE; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; LONG TERMINAL REPEAT; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NEUROENDOCRINE SYSTEM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; SCID MOUSE;

ANDROGENS; ANIMALS; CELL DIVISION; CULTURE MEDIA, CONDITIONED; DIHYDROTESTOSTERONE; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION; IMMUNOBLOTTING; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PHOSPHOPYRUVATE HYDRATASE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SOLUBILITY; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036893609     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220561     Document Type: Article

References (52)

1. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD 2001 Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7:1273-1281
2. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP 1999 Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515
3. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540
4. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E 1992 The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41:665-669
5. Tilley WD, Buchanan G, Hickey TE, Bentel JM 1996 Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285
6. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS 1997 Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11:450-459
7. Feldman BJ, Feldman D 2001 The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45
8. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478
9. Sadar MD 1999 Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 274:7777-7783
10. Nazareth LV, Weigel NL 1996 Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271:19900-19907
11. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ 1999 Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59:279-284
12. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C 1999 From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96:5458-5463
13. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL 2000 Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275:24500-24505
14. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC 2000 HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841-6845
15. Culig Z, Hobisch A, Cronauer MV, Hittmair A, Radmayr C, Bartsch G, Klocker H 1995 Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J Urol 13:285-289
16. Byrne RL, Leung H, Neal DE 1996 Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol 77:627-633
17. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H 1996 Regulation of prostatic growth and function by peptide growth factors. Prostate 28:392-405
18. Dow JK, deVere White RW 2000 Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 55:800-806
19. Djavan B, Waldert M, Seitz C, Marberger M 2001 Insulin-like growth factors and prostate cancer. World J Urol 19:225-233
20. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET 2001 Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12:33-40
21. Freeman MR, Paul S, Kaefer M, Ishikawa M, Adam RM, Renshaw AA, Elenius K, Klagsbrun M 1998 Heparin-binding EGF-like growth factor in the human prostate: Synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. J Cell Biochem 68:328-338
22. Adam RM, Borer JG, Williams J, Eastham JA, Loughlin KR, Freeman MR 1999 Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate. Endocrinology 140:5866-5875
23. Kim J, Adam RM, Freeman MR 2002 Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 62:1549-1554
24. Nguyen HT, Bride SH, Badawy AB, Adam RM, Lin J, Orsola A, Guthrie PD, Freeman MR, Peters CA 2000 Heparin-binding EGF-like growth factor is up-regulated in the obstructed kidney in a cell- and region-specific manner and acts to inhibit apoptosis. Am J Pathol 156:889-898
25. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M 1997 Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 272:31730-31737
26. Janik P, Briand P, Hartmann NR 1975 The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 35:3698-3704
27. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E 1992 Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31:2393-2399
28. Berrevoets CA, Veldscholte J, Mulder E 1993 Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors. J Steroid Biochem Mol Biol 46:731-736
29. Russell PJ, Bennett S, Joshua A, Yu Y, Downing SR, Hill MA, Kingsley EA, Mason RS, Berry J 1999 Elevated expression of FGF-2 does not cause prostate cancer progression in LNCaP cells. Prostate 40:1-13
30. Cronauer MV, Nessler-Menardi C, Klocker H, Maly K, Hobisch A, Bartsch G, Culig Z 2000 Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Br J Cancer 82:39-45
31. Ropiquet F, Huguenin S, Villette JM, Ronfle V, Le Brun G, Maitland NJ, Cussenot O, Fiet J, Berthon P 1999 FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. Int J Cancer 82:237-243
32. Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE 1997 Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 15:1115-1120
33. Mehta PB, Robson CN, Neal DE, Leung HY 2000 Serum keratinocyte growth factor measurement in patients with prostate cancer. J Urol 164:2151-2155
34. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279:563-566
35. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M 2001 In vivo progression of LaPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61:6276-6280
36. Miyake H, Nelson C, Rennie PS, Gleave ME 2000 Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141:2257-2265
37. Miyake H, Pollak M, Gleave ME 2000 Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60:3058-3064
38. Lin J, Adam RM, Santiestevan E, Freeman MR 1999 The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59:2891-2897
39. Abrahamsson PA 1999 Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 6:503-519
40. Abrahamsson PA 1996 Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate Suppl 6:3-8
41. di Sant'Agnese PA 1998 Neuroendocrine differentiation in prostatic carcinoma: An update. Prostate Suppl 8:74-79
42. di Sant'Agnese PA, Cockett AT 1996 Neuroendocrine differentiation in prostatic malignancy. Cancer 78:357-361
43. Abrahamsson PA 1999 Neuroendocrine differentiation in prostatic carcinoma. Prostate 39:135-148
44. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH 1997 The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 158:171-174
45. Jiborn T, Bjartell A, Abrahamsson PA 1998 Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 51:585-589
46. Helpap B, Kollermann J, Oehler U 1999 Neuroendocrine differentiation in prostatic carcinomas: Histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol Int 62:133-138
47. Craft N, Shostak Y, Carey M, Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285
48. Grossmann ME, Huang H, Tindall DJ 2001 Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697
49. Craft N, Sawyers CL 1998 Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev 17:421-427
50. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J 1991 Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189-193
51. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G, Klocker H 1998 Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35:63-70
52. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP 1997 Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319